Nile Therapeutics, Inc. (NASDAQ: NLTX), a clinical-stage biopharmaceutical company, is focused on developing novel products designed to treat cardiovascular disease. CD-NP, the company’s lead compound, is a chimeric natriuretic peptide that is currently in clinical studies for an initial indication of acute decompensated heart failure. Additionally, the company is also developing CU-NP, a chimeric natriuretic peptide, and 2NTX-99, a small molecule with anti-atherothrombotic and nitric oxide donating properties. For further information, visit the Company’s web site at www.nilethera.com.
- 18 years ago
QualityStocks
Nile Therapeutics, Inc. (NASDAQ: NLTX)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Belden Inc. (NYSE: BDC) To Acquire RUCKUS Networks for $1.85 Billion
Belden (NYSE: BDC) announced it has entered into a definitive agreement to acquire RUCKUS Networks from Vistance Networks for approximately $1.85…
-
From Capital to Catalysts: Canamera Energy Metals Corp.’s (CSE: EMET) (OTCQB: EMETF) $10M Raise Sets the Stage for Rare Earth Exploration Momentum
Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF)and may include paid…
-
Forward Industries Inc. (NASDAQ: FWDI) Adds Digital Asset and Traditional Finance Executive Mark Brazier as Chief Financial Officer
Forward Industries has appointed experienced financial executive Mark Brazier to serve as Chief Financial Officer.…